197 related articles for article (PubMed ID: 10788528)
1. Cost-effectiveness of non-steroidal anti-inflammatory drugs (NSAIDs)-what makes a NSAID good value for money?
Freemantle N
Rheumatology (Oxford); 2000 Mar; 39(3):232-4. PubMed ID: 10788528
[No Abstract] [Full Text] [Related]
2. [New treatment of pain and fever in rheumatoid arthritis and arthrosis. The first cyclooxygenase-2 inhibitors show promising results].
Oliw E; Wollheim FA
Lakartidningen; 2000 Jun; 97(24):2942-4. PubMed ID: 10900877
[No Abstract] [Full Text] [Related]
3. Cost-effectiveness of cyclooxygenase-2 inhibitors in chronic arthritis.
Pellissier JM; Watson DJ; Kong SX; Straus WL
Ann Intern Med; 2004 May; 140(9):761; author reply 761-2. PubMed ID: 15126263
[No Abstract] [Full Text] [Related]
4. Summaries for patients. The cost-effectiveness of cyclooxygenase-2 inhibitors for treating chronic arthritis.
Ann Intern Med; 2003 May; 138(10):I39. PubMed ID: 12755582
[No Abstract] [Full Text] [Related]
5. [Tolerable pain therapy in rheumatism saves long-term costs. Despite this most COX-2 candidates receive conventional NSAID therapy].
MMW Fortschr Med; 2003 Jul; 145(29-30):61. PubMed ID: 12958786
[No Abstract] [Full Text] [Related]
6. The cox-2 inhibitors.
Strassels S
J Mass Dent Soc; 1999; 48(3):43-4. PubMed ID: 10808349
[No Abstract] [Full Text] [Related]
7. The cost of COX inhibitors: how selective should we be?
Marra CA; Esdaile JM; Sun H; Anis AH
J Rheumatol; 2000 Dec; 27(12):2731-3. PubMed ID: 11128654
[No Abstract] [Full Text] [Related]
8. The cost-effectiveness of cyclooxygenase-2 selective inhibitors in the management of chronic arthritis.
Spiegel BM; Targownik L; Dulai GS; Gralnek IM
Ann Intern Med; 2003 May; 138(10):795-806. PubMed ID: 12755551
[TBL] [Abstract][Full Text] [Related]
9. Selective COX-2 inhibitors: a health economic perspective.
Schwappach DL; Koeck CM
Wien Med Wochenschr; 2003; 153(5-6):116-22. PubMed ID: 12705064
[TBL] [Abstract][Full Text] [Related]
10. COX-2 inhibitors. Magic bullets or merely mortal?
Harv Health Lett; 2000 Feb; 25(4):4. PubMed ID: 10637015
[No Abstract] [Full Text] [Related]
11. Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.
Moore A; Phillips C; Hunsche E; Pellissier J; Crespi S
Pharmacoeconomics; 2004; 22(10):643-60. PubMed ID: 15244490
[TBL] [Abstract][Full Text] [Related]
12. Incremental cost-effectiveness analysis comparing rofecoxib with nonselective NSAIDs in osteoarthritis: Ontario Ministry of Health perspective.
Marshall JK; Pellissier JM; Attard CL; Kong SX; Marentette MA
Pharmacoeconomics; 2001; 19(10):1039-49. PubMed ID: 11735672
[TBL] [Abstract][Full Text] [Related]
13. Celecoxib for the treatment of pain and inflammation: the preclinical and clinical results.
Tindall E
J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S13-7. PubMed ID: 10643176
[TBL] [Abstract][Full Text] [Related]
14. New directions in symptomatic therapy for patients with osteoarthritis and rheumatoid arthritis.
Hochberg MC
Semin Arthritis Rheum; 2002 Dec; 32(3 Suppl 1):4-14. PubMed ID: 12528069
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of low dose corticosteroids versus non-steroidal anti-inflammatory drugs and COX-2 specific inhibitors in the long-term treatment of rheumatoid arthritis.
Bae SC; Corzillius M; Kuntz KM; Liang MH
Rheumatology (Oxford); 2003 Jan; 42(1):46-53. PubMed ID: 12509612
[TBL] [Abstract][Full Text] [Related]
16. [Clinical use of COX-2 inhibitors].
Ristić GG; Stefanović DZ
Vojnosanit Pregl; 2001; 58(3):283-95. PubMed ID: 11548555
[No Abstract] [Full Text] [Related]
17. COX-1-sparing NSAIDs--is the enthusiasm justified?
Peterson WL; Cryer B
JAMA; 1999 Nov; 282(20):1961-3. PubMed ID: 10580464
[No Abstract] [Full Text] [Related]
18. Are the biologic and clinical effects of the COX-2-specific inhibitors an advance compared with the effects of traditional NSAIDs?
Simon LS
Curr Opin Rheumatol; 2000 May; 12(3):163-70. PubMed ID: 10803743
[TBL] [Abstract][Full Text] [Related]
19. Controversies in COX-2 inhibitor therapy: closing remarks.
Abramson SB; Furst DE; Hochberg MC; Patrono C
Clin Exp Rheumatol; 2001; 19(6 Suppl 25):S77-80. PubMed ID: 11695257
[No Abstract] [Full Text] [Related]
20. [Non-steroidal anti-inflammatory drugs and cyclooxygenase-2-specific inhibitors].
Miehle W
Wien Med Wochenschr; 1999; 149(19-20):541-5. PubMed ID: 10637962
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
